We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Assessment of Tau Protein Status for Early Detection of Alzheimer's Disease

By LabMedica International staff writers
Posted on 03 Jan 2017
The ratio of normal to aggregated tau protein found in blood platelets has been suggested as a biomarker that could be used for the early detection of Alzheimer's disease.

Investigators at the University of Chile (Santiago, Chile) previously had established the methodology that enables detection of the pathological oligomeric forms of brain tau protein in human blood platelets in patients with Alzheimer's disease (AD) and other neurodegenerative disorders.

The current study cited the use of this methodology to determine whether high molecular weight (HMW) or low molecular weight (LMW) tau protein levels, as well as the ratio HMW/LMW, present in platelets correlated with brain magnetic resonance imaging (MRI) structural changes in normal and cognitively impaired subjects. More...
The investigators examined 53 AD patients and 37 cognitively normal subjects recruited from two memory clinics at the University of Chile. Tau levels in platelets were determined by immunoreactivity and corresponding MRI scans were analyzed.

Results published in the December 20, 2016, issue of the Journal of Alzheimer's Disease revealed that the HMW/LMW tau ratio was statistically different between controls and AD patients, and no associations were noted between HMW or LMW tau and MRI structures. The HMW/LMW tau ratio was associated with reduced volume in the left medial and right anterior cingulate gyri, right cerebellum, right thalamus (pulvinar), left frontal cortex, and right parahippocampal region.

The investigators concluded that this exploratory study showed that the HMW/LMW tau ratio was significantly higher in AD patients than control subjects, and that it was associated with the atrophy of specific regions in the brain. Determination of peripheral markers of AD pathology could help in understanding the pathophysiology of neurodegeneration in AD.

Related Links:
University of Chile


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The assay serves as an adjunctive tool in evaluating patients suspected of B-cell lymphoproliferative disorders (photo courtesy of Shutterstock)

First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies

Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.